Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Neuromuscular Blockade Reversal in Morbidly Obese Patients
NCT01629394Phase 3Unknown
- Sponsor
- University of Patras
- Start
- Jan 2012
- Primary completion
- Oct 2012
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB) (8 arms), sponsored by University of Patras. Primary endpoint: Speed of reversal of neuromuscular blockade. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT01629394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01629394.